Loss of protein could contribute to early breast and ovarian cancer deaths

February 1, 2011, Yorkshire Cancer Research

(PhysOrg.com) -- The loss of a cell repair protein in a large proportion of women battling breast or ovarian cancer could explain why they die early, new research suggests.

Scientists at the University of Leeds, funded by Yorkshire Cancer Research and Campaign, have discovered that the loss of the human protein MCPH1 in cancer cells correlates with the large number of women who undergo surgery and chemotherapy to kill residual cancer cells but yet still die early because they are resistant to it.

The protein MCPH1 helps cells repair DNA damage and influences the function of the genes and BRCA2, certain variations of which are associated with a sharp increased risk of developing breast and or ovarian cancer.

The Leeds scientists have found that in 319 breast cancer sufferers and 47 ovarian cancer sufferers who have undergone surgery and chemotherapy, 29 percent of those breast cancer patients and 19 percent of those ovarian patients are deficient in MCPH1, particularly those with fast developing ovarian cancer and those resistant to chemotherapy.

University of Leeds Senior Research Fellow at Leeds Institute of (LIMM) Dr Sandra Bell said: "This is an exciting discovery. We have found that the reduced levels of MCPH1 in these breast and patients are associated with increasing tumour grade and poor survival.

"We have also demonstrated that MCPH1 regulates resistance to the chemotherapeutic drugs Paclitaxel and Parp inhibitors in a mechanism yet to be defined so the fact it is not present in these patients' cancer cells open up a new therapeutic window.

"Yorkshire Cancer Research is now funding the use of a new technology to rapidly identify molecules which selectively kill cancer cells which have lost the MCPH1 protein but do not kill cells which contain it.

"The identification of these molecules should allow new chemotherapy drugs to be developed that are tailored for women with breast and ovarian cancers who are dying earlier than expected because they are resistant to current chemotherapies."

Related Stories

Recommended for you

Probing RNA epigenetics and chromatin structures to predict drug resistance in leukemia

March 22, 2018
Drug resistance is a major obstacle to effective treatment for patients with cancer and leukemia. Epigenetic modifying drugs have been proven effective for some patients with hematologic malignancies, such as myelodysplastic ...

Gene-based test for urine detects, monitors bladder cancer

March 22, 2018
Researchers at The Johns Hopkins Kimmel Cancer Center have developed a test for urine, gathered during a routine procedure, to detect DNA mutations identified with urothelial cancers.

Researchers identify compound to prevent breast cancer cells from activating in brain

March 22, 2018
Researchers at Houston Methodist used computer modeling to find an existing investigational drug compound for leukemia patients to treat triple negative breast cancer once it spreads to the brain.

Could a pap test spot more than just cervical cancer?

March 22, 2018
Pap tests have helped drive down rates of cervical cancer, and a new study suggests they also could be used to detect other gynecologic cancers early.

Three-in-one molecule shows promise in helping certain breast cancer patients

March 22, 2018
A newly designed three-part molecule could be the one answer patients with a certain form of breast cancer are looking for, scientists report.

Researchers discover new anti-cancer protein

March 21, 2018
An international team of researchers has discovered a new anti-cancer protein. The protein, called LHPP, prevents the uncontrolled proliferation of cancer cells in the liver. The researchers led by Prof. Michael N. Hall from ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.